Key Drivers
- Strong Liquidity
- Positive Cash Flow
- Profitability Slump
AIAI Summary
Bio-Rad should now be treated less as a pure quality-franchise story and more as a cash-rich turnaround bet, because strong liquidity and positive free cash flow cushion the downside but the recent quarterly loss means investors need proof that operating leverage and earnings can recover before the stock can sustainably reclaim the 300 level.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Positive Cash Flow
- •Profitability Slump
BIO remains financially resilient with strong liquidity and positive free cash flow, but a steep quarterly net loss and negative EBIT/EBITDA have sharply weakened near-term earnings support.
Price Behavior
Key Price Behavior Insights:
- •Failed Breakout
- •Support Rebound
- •Lower Closes
Over the last month, BIO has been choppy and slightly weaker, rebounding sharply off the $270 area but still failing to break and hold above $300–$307, leaving the short-term setup mildly negative.
Sharp rebound from $270.32 to about $300.79, showing buyers stepped in after selloffs
Sentiment & News
Key News Insights:
- •Dealmaking Momentum
- •Activist Catalyst
- •Asset Monetization
BIO 2026 highlighted biotech partnering, AI, and global expansion, while Bio-Rad stood out on activist-driven value unlocking, potential Sartorius stake monetization, and tighter capital allocation.
The news is modestly positive for Bio-Rad, as strategic pressure and asset actions could unlock value while sector-wide BIO 2026 attention supports visibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings